ID

22290

Descrizione

Study part: Adverse Events. A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"

Keywords

versioni (1)

1. 29/05/17 29/05/17 -

Titolare del copyright

Roche

Caricato su

29 maggio 2017

DOI

Per favore, per richiedere un accesso.

Licenza